JP5406040B2 - 医薬使用のためのリパーゼ変異体 - Google Patents

医薬使用のためのリパーゼ変異体 Download PDF

Info

Publication number
JP5406040B2
JP5406040B2 JP2009543078A JP2009543078A JP5406040B2 JP 5406040 B2 JP5406040 B2 JP 5406040B2 JP 2009543078 A JP2009543078 A JP 2009543078A JP 2009543078 A JP2009543078 A JP 2009543078A JP 5406040 B2 JP5406040 B2 JP 5406040B2
Authority
JP
Japan
Prior art keywords
lipase
seq
enzyme
amino acids
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009543078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010512795A5 (enExample
JP2010512795A (ja
Inventor
スベンセン，アラン
スクヨエット，ミシェル
ヤバー，デビー
レーマン ヒュリング クリステンセン，ラーズ
エスキルセン ラーセン，シグネ
ルンディン，ニーナ
ランサ，マイケル
コリン グレゴリー，ピーター
Original Assignee
ノボザイムス アクティーゼルスカブ
ノボザイムス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノボザイムス アクティーゼルスカブ, ノボザイムス，インコーポレイティド filed Critical ノボザイムス アクティーゼルスカブ
Publication of JP2010512795A publication Critical patent/JP2010512795A/ja
Publication of JP2010512795A5 publication Critical patent/JP2010512795A5/ja
Application granted granted Critical
Publication of JP5406040B2 publication Critical patent/JP5406040B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2009543078A 2006-12-21 2007-12-12 医薬使用のためのリパーゼ変異体 Active JP5406040B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87119606P 2006-12-21 2006-12-21
US60/871,196 2006-12-21
PCT/US2007/087168 WO2008079685A2 (en) 2006-12-21 2007-12-12 Lipase variants for pharmaceutical use

Publications (3)

Publication Number Publication Date
JP2010512795A JP2010512795A (ja) 2010-04-30
JP2010512795A5 JP2010512795A5 (enExample) 2011-02-03
JP5406040B2 true JP5406040B2 (ja) 2014-02-05

Family

ID=38043020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009543078A Active JP5406040B2 (ja) 2006-12-21 2007-12-12 医薬使用のためのリパーゼ変異体

Country Status (16)

Country Link
US (3) US8273348B2 (enExample)
EP (6) EP2455459B1 (enExample)
JP (1) JP5406040B2 (enExample)
KR (1) KR20090101930A (enExample)
CN (2) CN105112386A (enExample)
AR (1) AR064494A1 (enExample)
AU (1) AU2007337150A1 (enExample)
BR (1) BRPI0721103A2 (enExample)
CA (3) CA2961041C (enExample)
IL (1) IL198893A0 (enExample)
MX (1) MX2009006597A (enExample)
NO (1) NO20092729L (enExample)
RU (1) RU2009128067A (enExample)
TW (1) TW200829698A (enExample)
WO (1) WO2008079685A2 (enExample)
ZA (1) ZA200903598B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
HUE031042T2 (en) 2005-07-29 2017-06-28 Abbott Laboratories Gmbh Methods for producing pancreatin powder with low viral content
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
KR20090101930A (ko) * 2006-12-21 2009-09-29 노보자임스 에이/에스 약학적 사용을 위한 리파아제 변형체
MX2010009077A (es) * 2008-02-29 2010-09-24 Novozymes As Variante de enzima lipolitica con estabilidad mejorada y polinucleotidos que codifican para la misma.
US8637101B2 (en) 2008-02-29 2014-01-28 Dsm Ip Assets B.V. Lipases with high specificity towards short chain fatty acids and uses thereof
AR070498A1 (es) * 2008-02-29 2010-04-07 Procter & Gamble Composicion detergente que comprende lipasa
CN102652175B (zh) 2009-12-09 2016-02-10 宝洁公司 织物和家居护理产品
EP2734633B1 (en) 2011-07-22 2019-05-01 Novozymes North America, Inc. Processes for pretreating cellulosic material and improving hydrolysis thereof
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
CN110777016A (zh) * 2011-12-29 2020-02-11 诺维信公司 具有脂肪酶变体的洗涤剂组合物
CN104080908B (zh) * 2012-02-03 2018-02-06 诺维信公司 脂肪酶变体以及编码它们的多核苷酸
CN107988181A (zh) 2012-04-02 2018-05-04 诺维信公司 脂肪酶变体以及编码其的多核苷酸
EP3842531A1 (en) * 2012-10-12 2021-06-30 Danisco US Inc. Compositions and method comprising a lipolytic enzyme variant
EP4717756A2 (en) 2013-05-14 2026-04-01 Novozymes A/S Lipase variants and detergent compositions
EP3696264B1 (en) * 2013-07-19 2023-06-28 Danisco US Inc. Compositions and methods comprising a lipolytic enzyme variant
WO2016079305A1 (en) * 2014-11-20 2016-05-26 Novozymes A/S Alicyclobacillus variants and polynucleotides encoding same
WO2016087401A1 (en) * 2014-12-05 2016-06-09 Novozymes A/S Lipase variants and polynucleotides encoding same
US11268076B2 (en) * 2014-12-09 2022-03-08 Novozymes A/S Lipase variants and polynucleotides encoding same
WO2016164596A2 (en) 2015-04-07 2016-10-13 Novozymes A/S Methods for selecting enzymes having lipase activity
MX394221B (es) * 2015-07-01 2025-03-24 Novozymes As Metodos de reduccion de olor.
CN107995922B (zh) * 2015-07-03 2021-12-28 诺维信公司 在亚硫酸盐的存在下具有改进的稳定性的洗涤剂组合物
EP3485008B1 (en) * 2016-07-18 2024-01-31 Novozymes A/S Lipase variants, polynucleotides encoding same and the use thereof
EP3575398A4 (en) * 2017-01-30 2020-11-11 Nippon Medical School Foundation ADENO-ASSOCIATED VIRUS (AAV) CAPSIDE PROTEIN MUTANT
EP4567094A3 (en) * 2017-09-27 2026-01-07 Novozymes A/S Lipase variants and microcapsule compositions comprising such lipase variants
JP7114697B2 (ja) 2017-09-27 2022-08-08 ザ プロクター アンド ギャンブル カンパニー リパーゼを含む洗剤組成物
EP3749759A1 (en) * 2018-02-08 2020-12-16 Novozymes A/S Lipase variants and compositions thereof
US12269847B2 (en) * 2018-08-16 2025-04-08 Donaldson Company, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
CN111334369B (zh) * 2020-03-11 2022-10-21 陕西科技大学 一种酶法制备卵磷脂型pufa的方法
CN115803083A (zh) * 2020-06-24 2023-03-14 基利安股份公司 新脂肪酶
JP2023547450A (ja) * 2020-10-29 2023-11-10 ノボザイムス アクティーゼルスカブ リパーゼ変異体及びそのようなリパーゼ変異体を含む組成物
CN113846074B (zh) * 2021-10-20 2022-10-21 南京林业大学 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用
CN116732002A (zh) * 2022-03-01 2023-09-12 中国科学院天津工业生物技术研究所 一种耐受表面活性剂的脂肪酶变体及其应用
EP4525615A2 (en) 2022-05-14 2025-03-26 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
EP4544015A2 (en) * 2022-06-24 2025-04-30 Novozymes A/S Lipase variants and compositions comprising such lipase variants
CN121874157A (zh) * 2023-12-01 2026-04-17 青岛蔚蓝生物集团有限公司 一种脂肪酶突变体
TWI903491B (zh) * 2024-05-09 2025-11-01 國立高雄科技大學 水體與沉積物通量培養系統

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173590D0 (da) * 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US5869438A (en) 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
DK46693D0 (enExample) * 1993-04-23 1993-04-23 Novo Nordisk As
AU657278B2 (en) 1990-09-13 1995-03-09 Novo Nordisk A/S Lipase variants
FI932561L (fi) 1990-12-05 1993-06-04 Novo Nordisk As Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
FI934812A0 (fi) 1991-05-01 1993-10-29 Novo Nordisk As Stabiliserade entzymer
DK39693D0 (da) 1993-04-02 1993-04-02 Novo Nordisk As Enzym
AU7807394A (en) 1993-10-04 1995-05-01 Novo Nordisk A/S An enzyme preparation comprising a modified enzyme
DE69527835T2 (de) 1994-02-22 2003-04-10 Novozymes A/S, Bagsvaerd Methode zur herstellung einer variante eines lipolytischen enzymes
WO1996016177A1 (en) 1994-11-24 1996-05-30 Novo Nordisk A/S A process for producing polypeptides with reduced allergenicity
FI972443A7 (fi) 1994-12-07 1997-06-09 Novozymes As Polypeptidi, jonka allergeenisuus on vähentynyt
CN1165614C (zh) 1995-01-26 2004-09-08 诺沃奇梅兹有限公司 含有木聚糖酶的动物饲料添加剂
EP0839186B1 (en) 1995-07-14 2004-11-10 Novozymes A/S A modified enzyme with lipolytic activity
US6495357B1 (en) * 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
AU6655196A (en) 1995-08-11 1997-03-12 Novo Nordisk A/S Novel lipolytic enzymes
CA2277618A1 (en) 1997-01-10 1998-07-16 Novo Nordisk A/S Enzyme coupled with polymeric molecules for skin care
JP2001511162A (ja) 1997-02-06 2001-08-07 ノボ ノルディスク アクティーゼルスカブ 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体
ATE375387T1 (de) 1997-06-25 2007-10-15 Novozymes As Modifiziertes polypeptid
AU3247699A (en) 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
ATE328070T1 (de) * 1998-02-17 2006-06-15 Novozymes As Lipasevariante
AU6078899A (en) 1998-10-13 2000-05-01 Novozymes A/S A modified polypeptide with reduced immune response
ATE365210T1 (de) 1998-10-30 2007-07-15 Novozymes As Glykosylierte proteine mit reduzierter allergenität
ES2220114T3 (es) 1998-10-30 2004-12-01 Novozymes A/S Variantes de proteinas poco alergenicas.
US7312062B2 (en) * 1998-11-27 2007-12-25 Novozymes A/S Lipolytic enzyme variants
NZ511340A (en) 1998-11-27 2003-07-25 Novozymes As Lipolytic enzyme variants
ATE242003T1 (de) 1999-03-17 2003-06-15 Solvay Pharm Gmbh Enzyme zur behandlung von diabetes mellitus typ i
AU3420100A (en) 1999-03-31 2000-10-23 Novozymes A/S Lipase variant
DK1428874T3 (en) * 1999-03-31 2014-03-10 Novozymes As lipase variant
CA2395266C (en) 2000-02-08 2009-04-14 F. Hoffmann-La Roche Ag Use of acid-stable subtilisin proteases in animal feed
EP1280817A2 (en) * 2000-04-28 2003-02-05 Novozymes A/S Production and use of protein variants having modified immunogenecity
AU2002219020B2 (en) * 2001-01-10 2007-05-24 Novozymes A/S Thermostable lipolytic enzyme variant
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
JP4287149B2 (ja) 2001-02-07 2009-07-01 ノボザイムス アクティーゼルスカブ リパーゼ変異体
EP1468084A1 (en) * 2002-01-16 2004-10-20 Novozymes A/S Lipolytic enzyme variants and method for their production
US20060234340A1 (en) 2003-02-06 2006-10-19 Novozymes A/S Human heavy chain antibody expression in flamentous fungi
CA2523400C (en) 2003-05-09 2015-03-17 Novozymes A/S Variant lipolytic enzymes
EP1639107B1 (en) 2003-06-19 2013-08-14 Novozymes A/S Improved proteases and methods for producing them
US20060251763A1 (en) 2003-06-19 2006-11-09 Patkar Shamkant A Phospholipase variants
JP2007535913A (ja) 2004-01-21 2007-12-13 ノボザイムス アクティーゼルスカブ ヘテロカリオン菌類又は菌類宿主細胞におけるモノクローナル抗体の生成
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
PT1809320E (pt) 2004-10-14 2010-10-25 Altus Pharmaceuticals Inc Composições contendo lipase, protease e amilase para o tratamento de insuficiência pancreática
EP1851311A2 (en) 2005-02-10 2007-11-07 Novozymes A/S Enzymatic enantioselective ester or amide hydrolysis or synthesis
AU2006261444A1 (en) 2005-06-24 2006-12-28 Novozymes A/S Amylases for pharmaceutical use
CN101208429A (zh) * 2005-06-24 2008-06-25 诺维信公司 用于药物用途的脂肪酶
NZ563777A (en) 2005-06-24 2010-08-27 Novozymes As Serine protease derived from Bacillus licheniformis optionally in combination with lipases and amylases for pharmaceutical use
WO2007080197A2 (en) * 2006-01-16 2007-07-19 Novozymes A/S Immobilised enzymes
EP1979456A2 (en) * 2006-01-23 2008-10-15 The Procter & Gamble Company A composition comprising a lipase and a bleach catalyst
CN101370933B (zh) * 2006-01-23 2015-11-25 诺维信公司 脂肪酶变体
KR20090101930A (ko) * 2006-12-21 2009-09-29 노보자임스 에이/에스 약학적 사용을 위한 리파아제 변형체

Also Published As

Publication number Publication date
US9029115B2 (en) 2015-05-12
EP2455462B1 (en) 2016-03-16
IL198893A0 (en) 2010-02-17
WO2008079685A2 (en) 2008-07-03
CA2961041A1 (en) 2008-07-03
CN101743308B (zh) 2015-09-16
CA2670643A1 (en) 2008-07-03
US20100034797A1 (en) 2010-02-11
EP2455461A2 (en) 2012-05-23
CA2670643C (en) 2017-04-25
MX2009006597A (es) 2009-07-02
EP2455462A2 (en) 2012-05-23
AR064494A1 (es) 2009-04-08
EP2455462A3 (en) 2013-05-29
CA3081308A1 (en) 2008-07-03
BRPI0721103A2 (pt) 2014-03-04
EP2455460A3 (en) 2012-12-26
KR20090101930A (ko) 2009-09-29
US20150209414A1 (en) 2015-07-30
CA3081308C (en) 2024-02-20
CA2961041C (en) 2020-07-14
CN101743308A (zh) 2010-06-16
ZA200903598B (en) 2010-04-28
JP2010512795A (ja) 2010-04-30
EP2099907A2 (en) 2009-09-16
EP2455461B1 (en) 2016-03-16
EP2261328B1 (en) 2013-11-20
US8273348B2 (en) 2012-09-25
EP2455461A3 (en) 2013-05-29
EP2455459A3 (en) 2013-04-24
AU2007337150A1 (en) 2008-07-03
WO2008079685A3 (en) 2008-11-06
RU2009128067A (ru) 2011-01-27
TW200829698A (en) 2008-07-16
EP2455460A2 (en) 2012-05-23
CN105112386A (zh) 2015-12-02
EP2455459A2 (en) 2012-05-23
US9539311B2 (en) 2017-01-10
NO20092729L (no) 2009-09-18
US20120308543A1 (en) 2012-12-06
EP2455459B1 (en) 2016-03-16
EP2261328A1 (en) 2010-12-15

Similar Documents

Publication Publication Date Title
JP5406040B2 (ja) 医薬使用のためのリパーゼ変異体
US20090047266A1 (en) Lipases for Pharmaceutical Use
JP2008546396A (ja) 薬学的に使用するためのアミラーゼ
US8455235B2 (en) Protease variants for pharmaceutical use
AU2013203500B2 (en) Lipase variants for pharmaceutical use
AU2013200626B2 (en) Lipase variants for pharmaceutical use
HK1141553A (en) Lipase variants for pharmaceutical use
HK1113174A (en) Lipases for pharmaceutical use
HK1145697A (en) Protease variants for pharmaceutical use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101210

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20111219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131031

R150 Certificate of patent or registration of utility model

Ref document number: 5406040

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250